Weight-loss and diabetes drugs Ozempic and Wegovy see price cuts of up to 48%

Drugmaker Novo Nordisk has announced a significant reduction in the price of its semaglutide-based therapies, Ozempic and Wegovy, to help improve accessibility for patients in India.

Effective from April 1, 2026, the starting dose of Ozempic will be available at a price reduced by 36%, while Wegovy's starting dose price will be cut by 48%.

The new pricing sets the effective daily cost at Rs. 202, or Rs. 1,415 per week for the 0.25 mg



doses of both Ozempic and Wegovy, inclusive of taxes.

The new Ozempic pen 0.25 mg costs Rs 1,415 per week, the 0.5 mg costs Rs 2,025 per week and the 1 mg costs Rs 2,275 per week. In the same manner, the Wegovy pen 0.25 mg costs Rs 1,415 against the previous price of Rs 2,712 per week.

This move is intended to make these globally recognised therapies more affordable for people managing type 2 diabetes and obesity in India.